Patent ID: 7105154

Claim:
A method for treating a condition responsive to interferon tau therapy, wherein the condition is selected from an autoimmune condition, cancer, or a viral infection, in a human subject, comprising orally administering interferon-tau to the intestinal tract of the subject in an amount effective to produce a measurable increase in the subject's blood 2′, 5′-oligoadenylate synthetase (OAS) level, relative to the blood OAS level in the subject in the absence of interferon-tau administration, as evidenced by monitoring the subject's blood OAS level to ascertain if the OAS level is increased following said administering, wherein said amount of interferon-tau is at least about 4.9×10 8 Units/day, and continuing to administer interferon-tau to the intestinal tract of the subject in such effective amount, on a regular basis of at least several times per week, for a period of at least one month, independent of changes in the subject's blood OAS level.